A major study to understand cannabis impairment reaches its conclusion
It is known that cannabis consumption in humans could cause alterations in cognitive functions. However, it has not been clear whether these alterations are reversible after abstinence, especially in subjects with prolonged consumption. Many opponents continue to claim that marijuana impairs memory because tetrahydrocannabinol (THC) alters the way the hippocampus, an area of the brain responsible for memory formation, processes information. These data are generally drawn from animal tests. Gaize has come to change the game after completing the world’s largest cannabis impairment clinical trial.
With the participation of 350 subjects, Gaize has conducted a large-scale clinical trial to further study the impairment caused by marijuana. The study, considered the largest in the world to date, set out to analyze changes in pupillary reflex action and eye movement between sober and marijuana-impaired participants.
In order to carry out this process, the research used Gaize’s portable, non-invasive testing device to investigate such eye activities. As is well known, the precise characteristics of eye movement and the changes that occur as a result of impairment have not been adequately investigated. The authors wanted to see how cannabis affected this process.
The trial, conducted in alliance with dicentra, a Contract Research Organization (CRO), focused on measurements of participants before and after they had consumed legally available cannabis. Rob Lass, Gaize’s chief technology officer, described the results of the study as “outstanding.
“We have really put our product through its paces,” Lass said. “Based on the data we gathered, we have been able to capture important insights into how cannabis impairment manifests in eye movement, and perform algorithmic optimization in preparation for the commercial launch.” Gaize is targeting a late 2022 release for the product.